Glutathione
FDA ApprovedThe master antioxidant and most abundant intracellular thiol in mammalian cells. This naturally occurring tripeptide (glutamate-cysteine-glycine) is essential for detoxification, immune function, and cellular protection. Extensively studied with strong mechanistic understanding and growing clinical evidence.
GSH · L-Glutathione · Reduced Glutathione · Gamma-Glutamylcysteinylglycine
20 human studies
- Preclinical
- 43%
- Clinical
- 57%
Based on 35 cited sources
clinically demonstrated · moderate confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 71: ≥2 independent placebo-controlled RCTs across distinct indications (Richie 24791752 6-month double-blind n=54 body stores; skin RCTs Weschawalit 28490897 and Watanabe 25378941; Hauser 19230029 PD RCT) plus an open-label NAFLD pilot (Honda 28789631) — 1A=30 (≥2 RCTs, no GSH-supplement meta-analysis), 1B=15 (Richie low-RoB but no high-confidence SR), 1C=6 (total human N ~190, 50–300 band), 1D=12 (direct oral route/population/outcome for core claims), 1E=8 (substantial decades-long preclinical program). Mechanism 94: enzymes/targets fully identified with genetic confirmation (GPx, glutathione reductase, GSTs; Nrf2/GCLC/GCLM regulation, Lu 22995213) — 2A=40, 2B=28 (full redox + Phase II pathway), 2C=16 (dose-dependent body stores in vivo), 2D=10. Plausibility 81: 3A=32 (full mechanism→surrogate→outcome for oxidative/skin claims; surrogate-only for neuroprotection), 3B=24 (coherent with redox physiology), 3C=17 (NAC/ALA class analogues), 3D=8 (moderately broad multi-system claim). Global Coverage 82: reproduced across independent groups and countries (USA, Japan, Thailand, Philippines, Italy) — 4A=28, 4B=22, 4C=22 (broad literature), 4D=10 (GRAS / clinical IV use). Community Experience 84: large, multi-year, well-documented wellness/beauty use (IV med spas, oral/ topical) — 5A=28, 5B=28, 5C=15 (consistent themes; oral-efficacy debate), 5D=13 (no recurring serious adverse signal). Effectiveness basis clinical (moderate): primary indication oxidative-stress/antioxidant status — 30–35% body-store increase and ~20% GSSG-ratio reduction (Richie), skin melanin/wrinkle RCTs, and NAFLD ALT improvement are moderate, largely surrogate/intermediate endpoints (E1 15 / E2 11 / E3 8 / E4 11 = 45); confidence moderate given small N, biomarker-heavy outcomes, and a null hard-outcome PD RCT (19230029).
Glutathione is the most abundant intracellular antioxidant in mammalian cells, with well-characterized biochemistry supported by decades of research.
How It Works (Simplified)
Glutathione functions as a “master antioxidant” through several interconnected pathways:
Donates electrons to neutralize reactive oxygen species (ROS), preventing DNA, protein, and lipid damage before it occurs.
Conjugates to drugs and environmental toxins via glutathione S-transferases, making them water-soluble for excretion.
Regenerates vitamin C and vitamin E back to their active forms after they neutralize free radicals, amplifying antioxidant capacity.
Maintains T cell and NK cell function. Adequate intracellular GSH is required for lymphocyte proliferation and cytotoxic activity.
Key Research: Richie JP et al. (2015) demonstrated that 6-month oral GSH supplementation increased body stores by 30-35%. PMID:24791752
Important Limitations
- Oral bioavailability historically debated; newer forms (liposomal, sublingual) show improved absorption
- GSH levels decline 10-15% per decade after age 20, accelerating in chronic disease
- Plasma half-life is short (~15-30 minutes); intracellular turnover varies by tissue
- Some clinical trials show inconsistent results depending on delivery method and population studied
Reported positives
- Improved skin brightness and complexion widely reported
- General detoxification and wellbeing benefits cited
- Well-tolerated across IV, oral, and topical forms
- Widely available in wellness clinics
Reported negatives
- Oral bioavailability very poor without liposomal form
- IV administration required for reliable systemic effects
- Skin lightening effects may be unwanted
- Effects temporary requiring ongoing supplementation
“Popular in wellness and beauty communities. IV glutathione widely offered in med spas and wellness clinics.”
Self-reported, unverified accounts — not clinical evidence and no substitute for the cited research. Anecdotes are prone to selection bias and placebo effects.
| NCT ID | Title | Peptide | Phase | Status | Completion |
|---|---|---|---|---|---|
| NCT01962376 | Glutathione in Cystic Fibrosis | Glutathione | Phase 2 | Completed | - |
| NCT00185562 | IV Glutathione in Parkinson's Disease | Glutathione | Phase 2 | Completed | - |
| NCT02324426 | Liposomal Glutathione in HIV | Glutathione | Phase 1/2 | Completed | - |
Initial increases in plasma GSH levels may be observed. Liposomal forms show measurable increases in whole blood GSH within 1-2 weeks. Immune cell function improvements noted in some studies.
PMID:28853742Continued accumulation of GSH in tissues. Clinical studies show significant increases in body stores by 4 weeks with consistent supplementation. Skin appearance improvements may begin.
PMID:28490897Optimal benefits typically observed with sustained supplementation. Studies show 30-35% increases in body stores by 3-6 months. Liver function improvements noted in NAFLD studies at 4 months.
PMID:24791752Long-term supplementation maintains elevated GSH levels. Benefits appear to be sustained with continued use. Discontinuation may result in gradual return to baseline levels.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
N-Acetylcysteine
SynergisticNAC is the primary precursor for GSH synthesis. Combining exogenous GSH with NAC may support both direct antioxidant activity and endogenous GSH production through complementary pathways.
Alpha-Lipoic-Acid
SynergisticAlpha-lipoic acid regenerates GSH and supports the GSH/GSSG redox cycle. Both compounds participate in antioxidant network recycling and may have complementary benefits.
Vitamin-C
SynergisticGSH regenerates oxidized vitamin C (dehydroascorbate) back to active ascorbate. This antioxidant recycling relationship suggests complementary benefits when combined.
BPC-157
CompatibleNon-overlapping mechanisms. GSH provides systemic antioxidant support while BPC-157 targets tissue repair pathways. No known contraindications.
Acetaminophen
CautionAcetaminophen depletes hepatic GSH stores during metabolism. High-dose acetaminophen use may increase GSH requirements; monitor liver function.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Glutathione
Related Peptides
Endoluten
Pineal cytamin · Pineal gland peptides · A-8 pineal peptides
A cytamin-class peptide supplement derived from pineal gland tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for pineal function and melatonin support. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Epithalon
Epitalon · Epithalone · AGAG +1
A synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to activate telomerase and extend lifespan. 2025 independent Western research confirmed telomerase activation in vitro. Still not approved anywhere; no controlled human clinical trials.
FOXO4-DRI
FOXO4-D-Retro-Inverso · FOXO4-DRI Peptide · Proxofim
A D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction, selectively eliminating senescent cells (senolytic). Preclinical studies in aged mice demonstrated restored fitness, fur density, and renal function. No human clinical trials conducted. More selective than BCL-2 inhibitors but remains unproven in humans.
Humanin
HN · HNG · S14G-Humanin +2
A 24-amino acid mitochondria-derived peptide (MDP) discovered in 2001 that shows cytoprotective, anti-apoptotic, and neuroprotective effects in preclinical studies. Represents a novel class of signaling molecules encoded within mitochondrial DNA. Extensive academic research with emerging interest in aging, metabolic disease, and neurodegeneration, but no approved clinical applications.
Klotho
Alpha-Klotho · KL protein · Anti-aging protein
An anti-aging transmembrane protein linked to longevity in animal models. Mouse studies demonstrate 15-20% lifespan extension. Primate cognition data published in Nature Aging. Klotho Neurosciences developing therapeutic applications for neurodegenerative disease.
MOTS-c
Mitochondrial ORF of the 12S rRNA type-c · Mitochondrial-derived peptide · MOTS-C peptide
A 16-amino acid mitochondrial-derived peptide encoded in mtDNA that targets AMPK/mTOR pathways for metabolic regulation. Preclinical studies show exercise mimetic and geroprotective effects. Lower MOTS-c levels found in T2D patients. No clinical trials yet conducted in humans.